ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis €0.13 0.00 (0.00%) As of 04/30/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Medigene Stock (ETR:MDG1) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medigene alerts:Sign Up Key Stats Today's Range€0.13▼€0.1350-Day Range€0.13▼€1.7552-Week Range€1.60▼€5.51VolumeN/AAverage Volume306,207 shsMarket Capitalization$1.02 millionP/E RatioN/ADividend Yield1.31%Price TargetN/AConsensus RatingN/A Company OverviewMedigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More… Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address MDG1 Stock News HeadlinesPTA-News: Medigene AG: Medigene AG hat Eröffnung des Insolvenzverfahrens beantragt - Einberufung zur aoHV nach §92 AktG entfälltApril 29, 2025 | finanznachrichten.dePTA-Adhoc: Medigene AG: Medigene AG stellt Antrag auf Eröffnung eines InsolvenzverfahrensApril 7, 2025 | finanznachrichten.deSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 3, 2025 | Stansberry Research (Ad)Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent OfficeMarch 13, 2025 | markets.businessinsider.comMedigene and EpimAb to develop T cell engagers for solid tumoursFebruary 28, 2025 | finance.yahoo.comPTA-News: Medigene AG: Medigene und EpimAb Biotherapeutics schließen Co-Entwicklungspartnerschaft für TCR-gesteuerte T-Zell-Engager abFebruary 27, 2025 | finanznachrichten.deMedigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell EngagersFebruary 27, 2025 | markets.businessinsider.comPTA-News: Medigene AG: Medigene AG erweitert Patentportfolio um Patenterteilung für seine JOVI Technologie in den USAFebruary 20, 2025 | finanznachrichten.deSee More Headlines MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed this year? Medigene's stock was trading at €1.03 at the beginning of the year. Since then, MDG1 stock has decreased by 87.0% and is now trading at €0.13. View the best growth stocks for 2025 here. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income$-4,667,238.14 Net Margins-249.83% Pretax MarginN/A Return on Equity-80.38% Return on Assets-27.15% Debt Debt-to-Equity Ratio12.95 Current Ratio2.39 Quick Ratio5.85 Sales & Book Value Annual Sales$1.87 million Price / Sales0.54 Cash Flow€0.10 per share Price / Cash Flow1.37 Book Value€0.72 per share Price / Book0.18Miscellaneous Outstanding Shares7,619,243Free FloatN/AMarket Cap$1.02 million OptionableNot Optionable Beta0.84 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (ETR:MDG1) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Medigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.